Kantonsspital St.Gallen

Cruz HBR

Irene Schneider, Karin Fink & Daniel Weilenmann

abstract Post-market registry to evaluate the safety and efficacy of the Supraflex Cruz™ sirolimus-eluting coronary stent system in the treatment of all-comer patients with coronary artery disease
type of project clinical studies
status ongoing - follow up
start of project 2020
end of project 2022
study design Prospective, multi-center, open-label, single-arm registry designed to
enroll 1200 (800 non-High Bleeding Risk (non-HBR) and 400 HBR) allcomer patients with coronary artery disease in around 25 sites in 3
European countries (Switzerland, Germany & France).
Patients will receive at least one Supraflex Cruz™ sirolimus-eluting stent as per current practice and will be followed up for 12 months.
responsible person Dr. Daniel Weilenmann